Lin Gui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lin Gui has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Fei Ge
School of Biological and Food Engineering, Anhui Polytechnic University, Wuhu, People’s Republic of China
6 shared publications Wanzhen Li
School of Biological and Food Engineering, Anhui Polytechnic University, Wuhu, People’s Republic of China
5 shared publications- Weiwei Zhang
Anhui Polytechnic University
5 shared publications - Yugui Tao
School of Biological and Food Engineering
4 shared publications Jun Wang
School of Biological and Food Engineering, Anhui Polytechnic University, Wuhu, People’s Republic of China
3 shared publicationsLongbao Zhu
School of Biological and Food Engineering, Anhui Polytechnic University, Wuhu, Anhui 241000, People’s Republic of China
3 shared publications
Latest Publications
- 26 July 2025
- Published by Springer Nature in Current Microbiology
- Vol. 82 (9) , 1-14
Synthesis of ZIF-8 Coated MnO2 Functionalized Antibacterial Peptide Nanoparticles and Its Antibacterial and Wound-Healing Promotion Studies
Antibiotics, a milestone invention in modern medicine, have significantly improved human quality of life and serve as a primary weapon against bacterial infections. However, antibiotic abuse has led to the emergence and worsening of bacterial resistance, now a major global public health challenge. Therefore, the efficient use of nanoscale antimicrobial peptides (APs) as therapeutic and diagnostic agents offers a novel strategy to replace conventional antibiotics. In this study, we innovatively combined AP with manganese dioxide (MnO2) and zeolitic imidazolate framework-8 (ZIF-8) to develop a novel composite: ZIF-8-encapsulated and AP-loaded MnO2 (AP-MnO2@ZIF-8). This composite exhibited superior properties, including enhanced biocompatibility, excellent aqueous stability, and increased antibacterial activity. Both in vitro and in vivo AP-MnO2@ZIF-8 demonstrated potent efficacy against multidrug-resistant (MDR) Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). Its minimum inhibitory concentrations (MICs) were 20 μg/ml for E. coli and 39 μg/ml for S. aureus. Furthermore, colony-forming unit (CFU) assays showed that 150-μg/ml AP-MnO2@ZIF-8 reduced bacterial survival below 5%, indicating effective growth inhibition. Crucially, it significantly suppressed bacterial activity in S. aureus-infected mouse wound models. Compared to free AP or MnO2 alone, AP-MnO2@ZIF-8 showed significantly enhanced water solubility, bioavailability, and antibacterial activity. This work provides a foundation for developing AP-based antimicrobial strategies and offers a novel nanomaterial approach to combat the increasingly severe antibiotic resistance crisis. Graphical Abstract
- 26 July 2025
- Published by Springer Nature in Current Microbiology
- Vol. 82 (9) , 1-14
Synthesis of ZIF-8 Coated MnO2 Functionalized Antibacterial Peptide Nanoparticles and Its Antibacterial and Wound-Healing Promotion Studies
Antibiotics, a milestone invention in modern medicine, have significantly improved human quality of life and serve as a primary weapon against bacterial infections. However, antibiotic abuse has led to the emergence and worsening of bacterial resistance, now a major global public health challenge. Therefore, the efficient use of nanoscale antimicrobial peptides (APs) as therapeutic and diagnostic agents offers a novel strategy to replace conventional antibiotics. In this study, we innovatively combined AP with manganese dioxide (MnO2) and zeolitic imidazolate framework-8 (ZIF-8) to develop a novel composite: ZIF-8-encapsulated and AP-loaded MnO2 (AP-MnO2@ZIF-8). This composite exhibited superior properties, including enhanced biocompatibility, excellent aqueous stability, and increased antibacterial activity. Both in vitro and in vivo AP-MnO2@ZIF-8 demonstrated potent efficacy against multidrug-resistant (MDR) Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). Its minimum inhibitory concentrations (MICs) were 20 μg/ml for E. coli and 39 μg/ml for S. aureus. Furthermore, colony-forming unit (CFU) assays showed that 150-μg/ml AP-MnO2@ZIF-8 reduced bacterial survival below 5%, indicating effective growth inhibition. Crucially, it significantly suppressed bacterial activity in S. aureus-infected mouse wound models. Compared to free AP or MnO2 alone, AP-MnO2@ZIF-8 showed significantly enhanced water solubility, bioavailability, and antibacterial activity. This work provides a foundation for developing AP-based antimicrobial strategies and offers a novel nanomaterial approach to combat the increasingly severe antibiotic resistance crisis. Graphical Abstract
- 18 March 2025
- Published by Springer Nature in Tungsten
- Vol. 7 (3) , 601-618
Synthesis of bimetallic compounds derived from Polyvinylpyrrolidone modified-FeMo2S3 and ZnMo2S3 Mo-clusters and their antibacterial application against water-borne microorganisms
- 18 March 2025
- Published by Springer Nature in Tungsten
- Vol. 7 (3) , 601-618
Synthesis of bimetallic compounds derived from Polyvinylpyrrolidone modified-FeMo2S3 and ZnMo2S3 Mo-clusters and their antibacterial application against water-borne microorganisms
- 9 October 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (20) , 18880-18891
Antibacterial MoS2/CaCO3 Nanoplatform for Combined Photothermal, Photodynamic, and Nitric Oxide Therapy
- 9 October 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (20) , 18880-18891
Antibacterial MoS2/CaCO3 Nanoplatform for Combined Photothermal, Photodynamic, and Nitric Oxide Therapy
- 31 March 2023
- Published by IOP Publishing in Nanotechnology
- Vol. 34 (24) , 245101
Preparation of an amphiphilic peptide (P13) with proton sponge effect and analysis of its antitumor activity
In order to prevent drugs from being captured and degraded by the acidic environment of organelles, such as lysosomes, after entering cells, this study designed and synthesized a novel carrier amphiphilic polypeptide (DGRHHHLLLAAAA), designated P13, for use as a tumor-targeting drug delivery vehicle. The P13 peptide was synthesized by the solid phase synthesis method, and its self-assembly behavior and drug-loading capacity in aqueous solution were studied and characterized in vitro. Doxorubicin (DOX) was loaded by dialysis method, and P13 and DOX were mixed at a mass ratio of 6:1 to form regular rounded globules. The acid–base buffering capacity of P13 was investigated determined by acid–base titration. The results revealed that P13 had excellent acid–base buffering capacity, a critical micelle concentration value of about 0.000 21 g l−1, and the particle size of P13-Dox nanospheres was 167 nm. The drug encapsulation efficiency and drug loading capacity of micelles were 20.40 ± 1.21% and 21.25 ± 2.79%, respectively. At the concentration of 50 μg ml−1 of P13-DOX , the inhibition rate was 73.35%. The results of the in vivo antitumor activity assay in mice showed that P13-DOX also exhibited excellent inhibitory effect on tumor growth, compared with the tumor weight of 1.1 g in the control group, the tumor weight in the P13-DOX-treated group was only 0.26 g. Additionally, the results of hematoxylin and eosin staining of the organs showed that P13-DOX had no damaging effect on normal tissues. The novel amphiphilic peptide P13 with proton sponge effect designed and prepared in this study is expected to be a promising tumor-targeting drug carrier with excellent application potential.
- 31 March 2023
- Published by IOP Publishing in Nanotechnology
- Vol. 34 (24) , 245101
Preparation of an amphiphilic peptide (P13) with proton sponge effect and analysis of its antitumor activity
In order to prevent drugs from being captured and degraded by the acidic environment of organelles, such as lysosomes, after entering cells, this study designed and synthesized a novel carrier amphiphilic polypeptide (DGRHHHLLLAAAA), designated P13, for use as a tumor-targeting drug delivery vehicle. The P13 peptide was synthesized by the solid phase synthesis method, and its self-assembly behavior and drug-loading capacity in aqueous solution were studied and characterized in vitro. Doxorubicin (DOX) was loaded by dialysis method, and P13 and DOX were mixed at a mass ratio of 6:1 to form regular rounded globules. The acid–base buffering capacity of P13 was investigated determined by acid–base titration. The results revealed that P13 had excellent acid–base buffering capacity, a critical micelle concentration value of about 0.000 21 g l−1, and the particle size of P13-Dox nanospheres was 167 nm. The drug encapsulation efficiency and drug loading capacity of micelles were 20.40 ± 1.21% and 21.25 ± 2.79%, respectively. At the concentration of 50 μg ml−1 of P13-DOX , the inhibition rate was 73.35%. The results of the in vivo antitumor activity assay in mice showed that P13-DOX also exhibited excellent inhibitory effect on tumor growth, compared with the tumor weight of 1.1 g in the control group, the tumor weight in the P13-DOX-treated group was only 0.26 g. Additionally, the results of hematoxylin and eosin staining of the organs showed that P13-DOX had no damaging effect on normal tissues. The novel amphiphilic peptide P13 with proton sponge effect designed and prepared in this study is expected to be a promising tumor-targeting drug carrier with excellent application potential.
- Open Access
- 30 May 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (11) , 1865
Synthesis of a Two-Dimensional Molybdenum Disulfide Nanosheet and Ultrasensitive Trapping of Staphylococcus Aureus for Enhanced Photothermal and Antibacterial Wound-Healing Therapy
Photothermal therapy has been widely used in the treatment of bacterial infections. However, the short photothermal effective radius of conventional nano-photothermal agents makes it difficult to achieve effective photothermal antibacterial activity. Therefore, improving composite targeting can significantly inhibit bacterial growth. We inhibited the growth of Staphylococcus aureus (S. aureus) by using an extremely low concentration of vancomycin (Van) and applied photothermal therapy with molybdenum disulfide (MoS2). This simple method used chitosan (CS) to synthesize fluorescein 5(6)-isothiocyanate (FITC)-labeled and Van-loaded MoS2-nanosheet hydrogels (MoS2-Van-FITC@CS). After modifying the surface, an extremely low concentration of Van could inhibit bacterial growth by trapping bacteria synergistically with the photothermal effects of MoS2, while FITC labeled bacteria and chitosan hydrogels promoted wound healing. The results showed that MoS2-Van-FITC@CS nanosheets had a thickness of approximately 30 nm, indicating the successful synthesis of the nanosheets. The vitro antibacterial results showed that MoS2-Van-FITC with near-infrared irradiation significantly inhibited S. aureus growth, reaching an inhibition rate of 94.5% at nanoparticle concentrations of up to 100 µg/mL. Furthermore, MoS2-Van-FITC@CS could exert a healing effect on wounds in mice. Our results demonstrate that MoS2-Van-FITC@CS is biocompatible and can be used as a wound-healing agent.
- 30 May 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (11) , 1865
Open AccessSynthesis of a Two-Dimensional Molybdenum Disulfide Nanosheet and Ultrasensitive Trapping of Staphylococcus Aureus for Enhanced Photothermal and Antibacterial Wound-Healing Therapy
Photothermal therapy has been widely used in the treatment of bacterial infections. However, the short photothermal effective radius of conventional nano-photothermal agents makes it difficult to achieve effective photothermal antibacterial activity. Therefore, improving composite targeting can significantly inhibit bacterial growth. We inhibited the growth of Staphylococcus aureus (S. aureus) by using an extremely low concentration of vancomycin (Van) and applied photothermal therapy with molybdenum disulfide (MoS2). This simple method used chitosan (CS) to synthesize fluorescein 5(6)-isothiocyanate (FITC)-labeled and Van-loaded MoS2-nanosheet hydrogels (MoS2-Van-FITC@CS). After modifying the surface, an extremely low concentration of Van could inhibit bacterial growth by trapping bacteria synergistically with the photothermal effects of MoS2, while FITC labeled bacteria and chitosan hydrogels promoted wound healing. The results showed that MoS2-Van-FITC@CS nanosheets had a thickness of approximately 30 nm, indicating the successful synthesis of the nanosheets. The vitro antibacterial results showed that MoS2-Van-FITC with near-infrared irradiation significantly inhibited S. aureus growth, reaching an inhibition rate of 94.5% at nanoparticle concentrations of up to 100 µg/mL. Furthermore, MoS2-Van-FITC@CS could exert a healing effect on wounds in mice. Our results demonstrate that MoS2-Van-FITC@CS is biocompatible and can be used as a wound-healing agent.
- Open Access
- 1 April 2021
- Published by IOP Publishing in Materials Research Express
- Vol. 8 (4) , 045012
Construction of the targeted and pH-sensitive paclitaxel drug delivery system RGD/PTX@ZIF-90 and anti-tumor activity research
Tumors area common cause of morbidity and mortality. High treatment efficiency and low drug toxicity are key for effective tumor treatment. Here, the pH-sensitive material ZIF-90 was synthesized by the liquid-phase diffusion method for loading paclitaxel (PTX), and the targeting peptide (RGD) was prepared by the solid-phase synthesis method to modify it (RGD/PTX@ZIF-90). The skeleton of RGD/PTX@ZIF-90 collapses in the acidic tumor microenvironment, thereby releasing PTX and mediating the controlled release of the drug. ZIF-90 below 300 nm was obtained by adjusting the ratio of metal ions and organic ligands in the characterization experiment. In addition, in vitro drug release experiments showed that the drug release rate was greater at pH = 5.5 than at pH = 7.4. The lethal rate of RGD/PTX@ZIF-90 to human breast cancer cells (MCF-7) was 44.5%, which was higher than the lethal rate of PTX alone (37.3%) in the cytotoxicity experiment and apoptosis experiment. Uptake experiments revealed that RGD/PTX@ZIF-90 mainly existed in the cytoplasm of MCF-7, which suggests that the drug had successfully entered the cell to achieve the therapeutic effect. The loading of the nano-medicine carrier ZIF-90 and the modification of the targeting peptide RGD significantly improve the therapeutic effect of PTX and indicate that this system could be used to treat breast cancer.
- 1 April 2021
- Published by IOP Publishing in Materials Research Express
- Vol. 8 (4) , 045012
Open AccessConstruction of the targeted and pH-sensitive paclitaxel drug delivery system RGD/PTX@ZIF-90 and anti-tumor activity research
Tumors area common cause of morbidity and mortality. High treatment efficiency and low drug toxicity are key for effective tumor treatment. Here, the pH-sensitive material ZIF-90 was synthesized by the liquid-phase diffusion method for loading paclitaxel (PTX), and the targeting peptide (RGD) was prepared by the solid-phase synthesis method to modify it (RGD/PTX@ZIF-90). The skeleton of RGD/PTX@ZIF-90 collapses in the acidic tumor microenvironment, thereby releasing PTX and mediating the controlled release of the drug. ZIF-90 below 300 nm was obtained by adjusting the ratio of metal ions and organic ligands in the characterization experiment. In addition, in vitro drug release experiments showed that the drug release rate was greater at pH = 5.5 than at pH = 7.4. The lethal rate of RGD/PTX@ZIF-90 to human breast cancer cells (MCF-7) was 44.5%, which was higher than the lethal rate of PTX alone (37.3%) in the cytotoxicity experiment and apoptosis experiment. Uptake experiments revealed that RGD/PTX@ZIF-90 mainly existed in the cytoplasm of MCF-7, which suggests that the drug had successfully entered the cell to achieve the therapeutic effect. The loading of the nano-medicine carrier ZIF-90 and the modification of the targeting peptide RGD significantly improve the therapeutic effect of PTX and indicate that this system could be used to treat breast cancer.
- 1 September 2019
- Published by IOP Publishing in Materials Research Express
- Vol. 6 (11) , 115411
Amphiphilic polypeptide P23: design, synthesis, self-assembly and its encapsulation effect on doxorubicin
Polypeptides are a new type of drug carrier materials that have attracted extensive attention owing to their favorable properties like good biocompatibility and biodegradability. In this paper, we report the design and synthesis of a tumor-targeting amphiphilic polypeptide P23 (DGRKKKKAAVALLPAVLLALLAP) consisting of a hydrophilic head and hydrophobic tail containing the amino-acid sequences DGRKKKK and AAVALLPAVLLALLAP, respectively, which can self-assemble into nanospheres in an aqueous solution and encase doxorubicin (DOX). The ability for drug release and in-vitro release kinetics of the P23@DOX composite were thoroughly studied in simulated gastric juice, tumor microenvironment, and intestinal fluid models. Cytotoxicity tests demonstrated that the toxicity levels of P23 against cells were low, but P23@DOX was more cytotoxic to 4T1 tumor cells than pristine DOX, indicating that the tumor-targeting performance of P23@DOX was good and it could be used as a drug carrier in tumor-targeting drug delivery systems.
- 1 September 2019
- Published by IOP Publishing in Materials Research Express
- Vol. 6 (11) , 115411
Amphiphilic polypeptide P23: design, synthesis, self-assembly and its encapsulation effect on doxorubicin
Polypeptides are a new type of drug carrier materials that have attracted extensive attention owing to their favorable properties like good biocompatibility and biodegradability. In this paper, we report the design and synthesis of a tumor-targeting amphiphilic polypeptide P23 (DGRKKKKAAVALLPAVLLALLAP) consisting of a hydrophilic head and hydrophobic tail containing the amino-acid sequences DGRKKKK and AAVALLPAVLLALLAP, respectively, which can self-assemble into nanospheres in an aqueous solution and encase doxorubicin (DOX). The ability for drug release and in-vitro release kinetics of the P23@DOX composite were thoroughly studied in simulated gastric juice, tumor microenvironment, and intestinal fluid models. Cytotoxicity tests demonstrated that the toxicity levels of P23 against cells were low, but P23@DOX was more cytotoxic to 4T1 tumor cells than pristine DOX, indicating that the tumor-targeting performance of P23@DOX was good and it could be used as a drug carrier in tumor-targeting drug delivery systems.